Immunobiologics

Question 1

1st biologic developed to specifically target IL-1

Answer 1

Anakinra

letter A = 1st letter

Question 2

1st anti-IL17A biologic FDA approved for plaque Psoriasis

Answer 2

Secukinumab

Question 3

IgG human monoclonal antibody directed at IL-12p40 FDA approved for use in psoriasis, psoriatic arthritis, and Crohn Disease

Answer 3

Ustekinumab

*subsequent research identified IL-23 rather than IL-12 is the more important target of pathogenesis in psoriasis

Question 4

Human IgG targeting IL-23p19 FDA approved in 2017 for treatment of moderate to severe plaque psoriasis

Answer 4

Guselkumab

other biologics targeting IL-23p19:
> Tildrakizumab
> Risankizumab

Question 5

TNF-a participation in the pathogenesis of psoriasis

Answer 5

inhibits keratinocyte apoptosis
promotes keratinocyte proliferation

Question 6

Etanercept dosing for psoriasis?

Answer 6

50 mg twice weekly for 3 months, followed by 50 mg once weekly

*Adalimumab dosing:
initial dose: 80 mg, followed by 40 mg every 2 weeks starting 1 week after the initial dose

Question 7

Among the TNF inhibitors, what is the most commonly used for pustular psoriasis?

Answer 7

Infliximab

Question 8

FDA approved for the treatment of moderate-to-severe rheumatoid arthritis and for the treatment of relapsed or chemorefractory CD20+ non-Hodgkin lymphoma

Answer 8

Rituximab

*(Fitz: 375 mg/m2 weekly intervals)
Monitoring CBC, serum antibody levels every 2-3 months while on therapy

Question 9

Monoclonal antibody targeting IL-4Ra (which is shared by IL4 and IL13)

Answer 9

Dupilumab

first FDA approved for the treatment of moderate-to-severe atopic dermatitis

Question 10

Monoclonal antibody directed at neutrophil recruitment in psoriasis vulgaris

Answer 10

Tocilizumab

IL-6R antibody
Neutrophils are expressed in IL6 receptors which stimulate production of Th17